Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Studies in rodents have implicated various cytokines as paracrine mediators of increased osteoclastogenesis during estrogen deficiency, but increases in RANKL, the final effector of osteoclastogenesis, have not been demonstrated. Thus, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe. The cells were characterized as preosteoblastic marrow stromal cells (MSCs), T lymphocytes, or B lymphocytes by using Ab's against bone alkaline phosphatase (BAP), CD3, and CD20, respectively, in 12 premenopausal women (Group A), 12 early postmenopausal women (Group B), and 12 age-matched, estrogen-treated postmenopausal women (Group C). Fluorescence intensity of OPG-Fc-FITC, an index of the surface concentration of RANKL per cell, was increased in Group B over Groups A and C by two- to threefold for MSCs, T cells, B cells, and total RANKL-expressing cells. Moreover, in the merged groups, RANKL expression per cell correlated directly with the bone resorption markers, serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all three cell types and inversely with serum 17beta-estradiol for total RANKL-expressing cells. The data suggest that upregulation of RANKL on bone marrow cells is an important determinant of increased bone resorption induced by estrogen deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, estrogen deficiency is associated with an expansion of RANKL-and TNF-expressing T cells and B cells (27,28,30,31).”
From Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics (2016) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“RANKL levels were increased on the surface of bone marrow cells from early postmenopausal women who are estrogen deficient”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [48]
In the citing paper
“Moreover, estrogen stimulates these bone cells to produce osteoprotegerin (OPG), a decoy receptor of RANK in osteoclast, thus inhibiting osteoclastogenesis [19, 155–159].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [157]
In the citing paper
“In humans, estrogen deficiency is associated with increased RANKL expression by bone marrow osteoblastic, T and B cells, whereas estrogen treatment reversed this increase ( 76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
In the citing paper
“flow cytometry studies conducted with bone marrow aspirates from postmenopausal subjects showed that saturating levels of OPG did not reduce the ability of anti-TRAIL antibodies to recognize TRAIL-positive cells (76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“The expression of RANKL by T cells may be related, in part, to their function as immunoregulators, because targeted disruption of the RANKL gene results in mice lacking lymph nodes and with defective T and B lymphocyte differentiation (45).”
BackgroundSelf-citationManolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“For example, ERα knockout mice have short limbs and mild osteopenia (31), whereas a young adult male with homozygous null mutations of ERα had elongated limbs and a greater degree of osteopenia (32).”
BackgroundSuda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · cited 1×
“In an experimental mouse model of inflammatory arthritis, activated T lymphocytes expressing RANKL were shown to regulate the associated periarticular bone loss and joint destruction (46).”
BackgroundSelf-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Self-citation
Research works printed but not linked: 8
- 10.1210/jc.87.4.1443 · doi:10.1210/jc.87.4.1443 · Paper page
- 10.1210/en.142.12.5050 · doi:10.1210/en.142.12.5050 · Paper page
- 10.1210/en.140.9.4367 · doi:10.1210/en.140.9.4367 · Paper page
- 10.1210/en.142.6.2205 · doi:10.1210/en.142.6.2205 · Paper page
- 10.1210/jc.87.4.1550 · doi:10.1210/jc.87.4.1550 · Paper page
- 10.1210/en.141.12.4768 · doi:10.1210/en.141.12.4768 · Paper page
- Owen, 1988, Ciba Found. Symp., 136, 42
- 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6 · DOI
Cited by
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
Self-citationOsteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Self-citationBiology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells
Florencio-Silva, R., Sasso, G. R. D. S., Sasso-Cerri, E., Simões, M. J., & Cerri, P. S. (2015) · BioMed Research International · doi:10.1155/2015/421746 · Cited by 2,044
Pathogenesis of osteoporosis: concepts, conflicts, and prospects
Raisz, L. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27071 · Cited by 1,779
Genetic regulation of osteoclast development and function
Teitelbaum, S. L., & Ross, F. P. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1122 · Cited by 1,701
“A recent seminal report shows that women who lack oestrogen have higher expression of the important osteoclastogenic molecule RANKL on both osteoblasts and lymphocyte”
BackgroundFeng, X., & McDonald, J. M. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130203 · Cited by 1,272
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Khosla, S., Oursler, M. J., & Monroe, D. G. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.008 · Cited by 943
“Combined in vitro and in vivo studies have demonstrated that estrogen suppresses RANKL production by osteoblastic, T- and B-cells (34) and also increases production of the decoy receptor for RANKL, osteoprotegerin (OPG) (35, 36).”
Self-citationEstrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860
Eastell, R., O'Neill, T. W., Hofbauer, L. C., Langdahl, B., Reid, I. R., Gold, D. T., & Cummings, S. R. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.69 · Cited by 827
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Self-citationEffects of obesity on bone metabolism
Cao, J. J. (2011) · Journal of Orthopaedic Surgery and Research · doi:10.1186/1749-799x-6-30 · Cited by 765
“RANKL [39,43,44].”
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
“Increased expression and production of RANK ligand (RANKL), as seen with estrogen deprivation, is a central mechanism of osteoclast activation and increased bone resorption [8,9].”
BackgroundKenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
“Increased RANKL and reduced OPG result in enhanced osteoclastogenesis and decreased apoptosis.(151,152)”
BackgroundBench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 694
Self-citationTheoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics
Li, J.-Y., Chassaing, B., Tyagi, A. M., Vaccaro, C., Luo, T., Adams, J., Darby, T. M., Weitzmann, M. N., Mulle, J. G., Gewirtz, A. T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86062 · Cited by 643
“In humans, estrogen deficiency is associated with an expansion of RANKL- and TNF-expressing T cells and B cells (27, 28, 30, 31).”
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y.-C., Grazette, L., San Martin, J., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 623
“Excessive RANK ligand has been implicated in bone diseases associated with increased bone resorption, such as osteoporosis (23).”
BackgroundBiology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond
Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599
“Osteoporosis is associated with hormonal changes, such as decreased estrogen levels in post-menopausal women, and has been linked to increased RANKL levels on bone marrow cells of women exhibiting osteoporosis (113, 114).”
BackgroundThe role of estrogen and androgen receptors in bone health and disease
Manolagas, S. C., O'Brien, C. A., & Almeida, M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.179 · Cited by 574
Aging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 559
“In vitro and in vivo studies have also shown that estrogen suppresses RANKL production by osteoblastic cells and T and B lymphocytes [Eghbali-Fatourechi et al. 2003; Clowes et al. 2005].”
BackgroundA crucial role for thiol antioxidants in estrogen-deficiency bone loss
Lean, J. M., Davies, J. T., Fuller, K., Jagger, C. J., Kirstein, B., Partington, G. A., Urry, Z., & Chambers, T. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18859 · Cited by 547
“After 5 days, the medium was discarded and replaced with fresh medium containing M-CSF (50 ng/ml) and RANKL (30 ng/ml) with or without NAC (30 mM).”
InfluentialAn overview of the regulation of bone remodelling at the cellular level
Kular, J., Tickner, J., Chim, S. M., & Xu, J. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.03.021 · Cited by 534
“This is mediated by RANKL, generated from osteoblasts and other cell types, leading to increased bone resorption [138].”
BackgroundXu, F., & Teitelbaum, S. L. (2013) · Bone Research · doi:10.4248/br201301003 · Cited by 523
Li, Y., Toraldo, G., Li, A., Yang, X., Zhang, H., Qian, W.-P., & Weitzmann, M. N. (2007) · Blood · doi:10.1182/blood-2006-07-037994 · Cited by 520
Mundy, G. R. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00353.x · Cited by 478
Circulating Osteoblast-Lineage Cells in Humans
Eghbali-Fatourechi, G. Z., Lamsam, J., Fraser, D., Nagel, D., Riggs, B. L., & Khosla, S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044264 · Cited by 418
Self-citationOsteoporosis, inflammation and ageing
Ginaldi, L., Di Benedetto, M. C., & De Martinis, M. (2005) · Immunity & Ageing · doi:10.1186/1742-4933-2-14 · Cited by 412
“Calciotropic factors such as vitamin D3, PGE2, IL-1, IL-11, TNF-α and glucocorticoid induce RANKL expression on osteoblasts [36].”
BackgroundMechanisms of sex steroid effects on bone
Syed, F., & Khosla, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.097 · Cited by 380
Self-citationPathophysiology of Age-Related Bone Loss and Osteoporosis
Khosla, S., & Riggs, B. L. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.07.009 · Cited by 376
“The key, essential molecule for osteoclast development is the receptor activator of NF-kB ligand (RANKL) [14], which is expressed on the surface of bone marrow stromal/osteoblast precursor cells, T cells, and B cells [15].”
BackgroundSelf-citationThe role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 359
“There is a two- to three-fold increase in the mean RANKL fluorescence intensity per cell in group B (gray bars) over group A (white bars) and a smaller increase in group B (gray bars) over group C (black bars) using Student–Newman–Keuls test (80).”
BackgroundMethodInfluentialSelf-citationBone Remodeling in Post-menopausal Osteoporosis
Lerner, U. H. (2006) · Journal of Dental Research · doi:10.1177/154405910608500703 · Cited by 347
Reactive oxygen species mediate RANK signaling in osteoclasts
Ha, H., Bok Kwak, H., Woong Lee, S., Mi Jin, H., Kim, H.-M., Kim, H.-H., & Hee Lee, Z. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.07.035 · Cited by 347
Khosla, S., Melton, L. J., & Riggs, B. L. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.262 · Cited by 305
“Thus, by increasing osteoprotegerin (OPG)((45)) and decreasing receptor activator of nuclear kB ligand (RANKL)((46)) production by osteoblastic cells, as well as by suppressive effects on the production of tumor necrosis factor a (TNF-a)((47)) and other proresorptive cytokines,((48)) estrogen reduces osteoclastogenesi…”
BackgroundSelf-citationOsteoblast physiology in normal and pathological conditions
Neve, A., Corrado, A., & Cantatore, F. P. (2011) · Cell and Tissue Research · doi:10.1007/s00441-010-1086-1 · Cited by 331
D'Amelio, P., Grimaldi, A., Di Bella, S., Brianza, S. Z. M., Cristofaro, M. A., Tamone, C., Giribaldi, G., Ulliers, D., Pescarmona, G. P., & Isaia, G. (2008) · Bone · doi:10.1016/j.bone.2008.02.017 · Cited by 331
“Other reports show that estrogen deficiency increases the production of TNF and RANKL by bone marrow cells, including T cells, and that their increase correlatewith indices of bone resorption [20–22].”
BackgroundRegulation of Bone Metabolism by Sex Steroids
Khosla, S., & Monroe, D. G. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031211 · Cited by 323
“human studies showing increased RANKL expression on bone marrow stromal cells, T cells, and B cells in estrogen deficient as compared with estrogen-sufficient women (Eghbali-Fatourechi et al. 2003).”
BackgroundMethodInfluentialSelf-citationOvariectomy induces oxidative stress and impairs bone antioxidant system in adult rats
Muthusami, S., Ramachandran, I., Muthusamy, B., Vasudevan, G., Prabhu, V., Subramaniam, V., Jagadeesan, A., & Narasimhan, S. (2005) · Clinica Chimica Acta · doi:10.1016/j.cccn.2005.04.014 · Cited by 320
Tanaka, S., Nakamura, K., Takahasi, N., & Suda, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00327.x · Cited by 320
“RANKL expression per cell correlated well with the bone resorption markers serum C-terminal telopeptide of type I collagen and urine N-telopeptide (NTX) of type I collagen and inversely with serum 17bestradiol level (114).”
BackgroundLewiecki, E. M., Miller, P. D., McClung, M. R., Cohen, S. B., Bolognese, M. A., Liu, Y., Wang, A., Siddhanti, S., & Fitzpatrick, L. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070809 · Cited by 319
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass
Bonnet, N., Bourgoin, L., Biver, E., Douni, E., & Ferrari, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125915 · Cited by 314
“Increased expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in postmenopausal women plays a central role in the development of osteoporosis (5).”
The Pathophysiology and Treatment of Osteoporosis
Drake, M. T., Clarke, B. L., & Lewiecki, E. M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.06.006 · Cited by 290
Immunology of Osteoporosis: A Mini-Review
Pietschmann, P., Mechtcheriakova, D., Meshcheryakova, A., Föger-Samwald, U., & Ellinger, I. (2016) · Gerontology · doi:10.1159/000431091 · Cited by 287
Osteocyte RANKL: New insights into the control of bone remodeling
Xiong, J., & O'Brien, C. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1547 · Cited by 287
“However, cell surface RANKL is elevated in lymphocytes, as well as in cells that may be osteoblast progenitors, in the bone marrow of early postmenopausal women.((69)) Consistent with this, preliminary studies using the RANKL conditional allele have shown that the ovariectomy-induced loss of cancellous bone is blunted…”
BackgroundHypercalcemia of malignancy: An update on pathogenesis and management
Mirrakhimov, A. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.170600 · Cited by 290
“Factors that exert the opposite effects on bone turnover (such as estrogens) stimulate the release of osteoprotegerin from osteoblasts, binding RANKL, and preventing it from binding to RANK on the osteoclast precursor cell.[12-14]”
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281
Osteoporosis: An Age-Related and Gender-Specific Disease – A Mini-Review
Pietschmann, P., Rauner, M., Sipos, W., & Kerschan-Schindl, K. (2009) · Gerontology · doi:10.1159/000166209 · Cited by 262
“effects mediated by an upregulation of osteoprotegerin. As mentioned above, estrogen withdrawal results in a high remodeling rate with excessive bone resorption and rapid bone loss. Eghbali-Fatourechi et al. [”
BackgroundTotal oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis
Altindag, O., Erel, O., Soran, N., Celik, H., & Selek, S. (2008) · Rheumatology International · doi:10.1007/s00296-007-0452-0 · Cited by 260
“factor B ligand (NF-KB), osteoprotegerin (OPG), and NFKB, modulates osteoclast formation [28, 29].”
BackgroundWeitzmann, M. N. (2013) · Scientifica · doi:10.1155/2013/125705 · Cited by 259
“The surface concentration of RANKL per cell was increased in postmenopausal women compared to premenopausal women and estrogen-treated postmenopausal women by two- to threefold forMSCs, T cells, B cells, and total RANKLexpressing cells [242].”
BackgroundInfluentialOsteoporosis: Pathophysiology and therapeutic options
Föger‐Samwald, U., Dovjak, P., Azizi-Semrad, U., Kerschan‐Schindl, K., & Pietschmann, P. (2020) · EXCLI journal · doi:10.17179/excli2020-2591 · Cited by 257
“Indeed, production of RANKL by B-cells is increased in postmenopausal women (Eghbali-Fatourechi et al., 2003) and B-cell ablation of RANKL in mice partially protects from trabecular bone loss after ovariectomy (Onal et al., 2012).”
BackgroundUpdating osteoimmunology: regulation of bone cells by innate and adaptive immunity
Walsh, M. C., Takegahara, N., Kim, H., & Choi, Y. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2017.213 · Cited by 252
The OPG/RANKL/RANK system in metabolic bone diseases.
Hofbauer, L. C., Kühne, C. A., & Viereck, V. (2004) · PubMed · Cited by 311
Onal, M., Xiong, J., Chen, X., Thostenson, J. D., Almeida, M., Manolagas, S. C., & O'Brien, C. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377945 · Cited by 249
“Moreover, membrane-bound RANKL is increased on both B and T lymphocytes in the bone marrow of postmenopausal women not on estrogen replacement compared with either postmenopausal women on estrogen replacement or premenopausal women (19).”
BackgroundClarke, B. L., & Khosla, S. (2010) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2010.02.014 · Cited by 221
“RANKL is the final key molecule required for osteoclast development, and is normally expressed by bone marrow stromal/osteoblast precursor cells, T-lymphocytes, and B-lymphocytes [20,21].”
BackgroundSelf-citationEstrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells
Streicher, C., Heyny, A., Andrukhova, O., Haigl, B., Slavic, S., Schüler, C., Kollmann, K., Kantner, I., Sexl, V., Kleiter, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06614-0 · Cited by 251
Vega, D., Maalouf, N. M., & Sakhaee, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0646 · Cited by 246
“Moreover, in experiments using dual-color flow cytometry, human bone marrow cells from untreated early postmenopausal women exhibited a greater expression of RANKL compared with estrogen-treated postmenopausal women (23).”
ResultPhysiological and pathophysiological bone turnover — role of the immune system
Weitzmann, M. N., & Ofotokun, I. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.91 · Cited by 240
Charatcharoenwitthaya, N., Khosla, S., Atkinson, E. J., McCready, L. K., & Riggs, B. L. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070207 · Cited by 235
“In addition, estrogen may decrease the RANKL/osteoprotegerin (OPG) ratio in the bone microenvironment.((24,25))”
BackgroundSelf-citationOsteocyte control of osteoclastogenesis
O'Brien, C. A., Nakashima, T., & Takayanagi, H. (2013) · Bone · doi:10.1016/j.bone.2012.08.121 · Cited by 235
“Studies in estrogen-deficient women demonstrated that RANKL abundance is increased on the surface of bone marrow lymphocytes and stromal cells, compared to estrogen-replete women [75].”
BackgroundHenriksen, K., Bollerslev, J., Everts, V., & Karsdal, M. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0006 · Cited by 230
Impact of estrogens in males and androgens in females
Hammes, S. R., & Levin, E. R. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125755 · Cited by 225
“Other purported mediators of osteoclast development and/or resorption in females that are inhibited by estrogen include activation of NF-κΒ and sclerostin (16).”
BackgroundUpdates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune System
Ponzetti, M., & Rucci, N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00236 · Cited by 221
Pathogenesis of Age-Related Bone Loss in Humans
Khosla, S. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls163 · Cited by 222
“To assess this in humans, our group (16) isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated OPG-Rc as a probe.”
MethodSelf-citationRANKing Intracellular Signaling in Osteoclasts
Feng, X. (2005) · IUBMB Life (International Union of Biochemistry and Molecular Biology: Life) · doi:10.1080/15216540500137669 · Cited by 219
“Recently, it was shown that estrogen deficiency leads to the elevated expression of RANKL on both osteoblasts and lymphocytes and the increased RANKL expression plays a pathological role in the development of postmenopausal osteoporosis ( 14 ).”
BackgroundRogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
“Cell surface production of RANKL has been assessed in vivo in humans using flow cytometry (110).”
BackgroundSerum Adiponectin and Bone Mineral Density in Women
Richards, J. B., Valdes, A. M., Burling, K., Perks, U. C., & Spector, T. D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2097 · Cited by 214
“RANKL is a potent stimulus for bone resorption, and osteoprotegerin has been shown to prevent RANKL-induced bone loss (27).”
BackgroundModulation of bone remodeling by the gut microbiota: A new therapy for osteoporosis
Lyu, Z., Hu, Y., Guo, Y., & Liu, D. (2023) · Bone Research · doi:10.1038/s41413-023-00264-x · Cited by 207
Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts
Zupan, J., Jeras, M., & Marc, J. (2013) · Biochemia Medica · doi:10.11613/bm.2013.007 · Cited by 202
“It has been suggested that activated T cells could contribute to enhanced osteoclastogenesis in two ways, fi rst by increasing the production of bone resorbing cytokines, especially TNF-α and RANKL, and secondly, by increasing the numbers of osteoclast precursors (139,148).”
BackgroundCao, J. J., Wronski, T. J., Iwaniec, U., Phleger, L., Kurimoto, P., Boudignon, B., & Halloran, B. P. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050503 · Cited by 195
“(16–19) In humans, EghbaliFatourechi et al.(20) reported that estrogen deficiency associated with menopause increases RANKL expression in marrow cells.”
BackgroundDar, H. Y., Shukla, P., Mishra, P. K., Anupam, R., Mondal, R. K., Tomar, G. B., Sharma, V., & Srivastava, R. K. (2018) · Bone Reports · doi:10.1016/j.bonr.2018.02.001 · Cited by 194
Osteoclasts, Master Sculptors of Bone
Veis, D. J., & O'Brien, C. A. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-040919 · Cited by 193
The role of T lymphocytes in bone metabolism
Weitzmann, M. N., & Pacifici, R. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00324.x · Cited by 192
“increases in bone resorption markers and inversely with serum estrogen levels (141).”
BackgroundRANK, RANKL and osteoprotegerin in bone biology and disease
Wright, H. L., McCarthy, H. S., Middleton, J., & Marshall, M. J. (2009) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-009-9046-7 · Cited by 194
“related cytokine expressed by various bone cells including osteoblasts and their immature precursors [15], T lymphocytes [16], B lymphocytes [17] and megakaryocytes [18].”
BackgroundThe Interplay between the Bone and the Immune System
Mori, G., D'Amelio, P., Faccio, R., & Brunetti, G. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/720504 · Cited by 193
“RANKL from B cells isolated from the bone marrow of estrogen-deficient postmenopausal women has been demonstrated to secrete RANKL [163], providing a plausible mechanism for a role of B cells in estrogen deficiency-bone loss.”
BackgroundOsteoimmunology: A Current Update of the Interplay Between Bone and the Immune System
Guder, C., Gravius, S., Burger, C., Wirtz, D. C., & Schildberg, F. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00058 · Cited by 190
“Simply put, osteoporosis is an imbalance between bone destruction and development, with OC surpassing OB in activity (177).”
BackgroundKitaura, H., Sands, M. S., Aya, K., Zhou, P., Hirayama, T., Uthgenannt, B., Wei, S., Takeshita, S., Novack, D. V., Silva, M. J., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4838 · Cited by 190
“express increased amounts of the cytokine (5).”
The Potential of Probiotics as a Therapy for Osteoporosis
Collins, F. L., Rios-Arce, N. D., Schepper, J. D., Parameswaran, N., & McCabe, L. R. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0015-2016 · Cited by 184
“…increase expression of proin fl am-matory and osteogenic cytokines, namely, interleukin-1 (IL-1), IL-6, IL-7, tumor necrosis factor alpha (TNF α ), macrophage colony-stimulating factor (MCSF), and receptor activator of NF-κ B ligand (RANKL) from osteoblasts, as well as T cells and B cells (19 – 23).”
BackgroundIn vitro Models of Bone Remodelling and Associated Disorders
Owen, R., & Reilly, G. C. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00134 · Cited by 182
Pathogenesis of calciphylaxis: Hans Selye to nuclear factor κ-B
Weenig, R. H. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.12.006 · Cited by 183
Goëb, V., & Anne-Priscille, T. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s10153 · Cited by 179
“13 Studies on the effects of androgens have yielded conflicting results on their effects on OPG.”
Weitzmann, M. N. (2017) · Toxicologic Pathology · doi:10.1177/0192623317735316 · Cited by 177
“…in the human context remain few and far between, at least one examination of human bone marrow cells has revealed that both T cells and B cells produce significantly elevated concentrations of RANKL, in postmenopausal women compared to premenopausal controls (Eghbali-Fatourechi et al. 2003).”
BackgroundShen, C.-L., Yeh, J. K., Cao, J. J., & Wang, J.-S. (2009) · Nutrition Research · doi:10.1016/j.nutres.2009.06.008 · Cited by 178
“Eghbali-Fatourechi et al [168] reported that the surface expression of RANKL on marrow stromal cells, B cells, and T cells was significantly higher in early postmenopausal women when compared with premenopausal or estrogen-treated women.”
Onco-Nephrology: The Pathophysiology and Treatment of Malignancy-Associated Hypercalcemia
Rosner, M. H., & Dalkin, A. C. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02470312 · Cited by 178
“For example, osteoblast cells express estrogen receptors that when occupied with ligand can reduce RANKL and increase OPG (13).”
BackgroundInfluentialThe Biology of Bone Metastasis
Esposito, M., Guise, T., & Kang, Y. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031252 · Cited by 170
“Thus far, these studies have only shown higher expression on RANKL onbonemarrow–derived cells frommenopausal women versus premenopausal (Eghbali-Fatourechi et al. 2003), and that animals with experimentally induced osteoporosis by ovariectomy or mir-34 knockout suffer from increased bone metastasis…”
Strontium ranelate: New insights into its dual mode of action
Marie, P. J. (2007) · Bone · doi:10.1016/j.bone.2007.02.003 · Cited by 168
“Notably, the increased RANKL/OPG induced by estrogen deficiency results in acceleration of bone resorption and bone loss in postmenopausal women [36].”
BackgroundMartiniakova, M., Babikova, M., Mondockova, V., Blahova, J., Kovacova, V., & Omelka, R. (2022) · Nutrients · doi:10.3390/nu14030523 · Cited by 166
“Furthermore, estrogen loss during menopause can be consistent with an elevated expression of RANKL and reduced expression of osteoprotegerin (OPG), its natural antagonist by osteoblasts and osteocytes, thereby raising bone resorption in both trabecular and cortical bone compartments [10,17].”
BackgroundYu, M., Pal, S., Paterson, C. W., Li, J.-Y., Tyagi, A. M., Adams, J., Coopersmith, C. M., Weitzmann, M. N., & Pacifici, R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143137 · Cited by 162
Control of RANKL gene expression
O'Brien, C. A. (2010) · Bone · doi:10.1016/j.bone.2009.08.050 · Cited by 162
“Subsequently, studies in humans demonstrated that RANKL protein levels on B and T lymphocytes isolated from the bone marrow of post-menopausal women were elevated compared with pre-menopausal women or post-menopausal women treated with estrogen [80], suggesting that lymphocyte expression of RANKL may also play an impo…”
ResultEmerging therapeutic opportunities for skeletal restoration
Kawai, M., Mödder, U. I., Khosla, S., & Rosen, C. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3299 · Cited by 159
“, which is expressed on the surface of bone marrow stromal and/or osteoblast precursor cells, T cells and B cell”
BackgroundSelf-citationUpdate on Estrogens and the Skeleton
Khosla, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0856 · Cited by 158
Self-citationFemale reproductive system and bone
Clarke, B. L., & Khosla, S. (2010) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.07.006 · Cited by 154
Self-citationPostmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen
Lu, L., & Tian, L. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0116 · Cited by 193
NF-κB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism
Yao, Z., Xing, L., & Boyce, B. F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38716 · Cited by 149
Regulation of adult bone turnover by sex steroids
Frenkel, B., Hong, A., Baniwal, S. K., Coetzee, G. A., Ohlsson, C., Khalid, O. S., & Gabet, Y. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22159 · Cited by 161
“In addition, postmenopausal women have increased RANKL expression in pre-osteoblasts (as well as T- and B-cells) as compared either to premenopausal women or postmenopausal women on estrogen therapy (Eghbali-Fatourechi et al., 2003).”
BackgroundEstrogen deficiency, T cells and bone loss
Pacifici, R. (2008) · Cellular Immunology · doi:10.1016/j.cellimm.2007.06.008 · Cited by 146
Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats
Vikulina, T., Fan, X., Yamaguchi, M., Roser-Page, S., Zayzafoon, M., Guidot, D. M., Ofotokun, I., & Weitzmann, M. N. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003020107 · Cited by 145
“Although, many cell types are capable of making RANKL and OPG, B cells are recognized as a significant source of RANKL when activated in vitro (13), in postmenopausal humans in vivo (3), and in inflammatory conditions such as periodontitis (14).”
BackgroundRole of T cells in ovariectomy induced bone loss—revisited
Pacifici, R. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1500 · Cited by 142
“Studies have also shown that menopause increases T cell activation and T cell production of TNF and RANKL in humans.((42,43)) The role of TNF in ovx-induced bone loss has been demonstrated in multiple models.”
BackgroundThe management of osteoporosis in children
Ward, L. M., Konji, V. N., & Ma, J. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3515-9 · Cited by 151
“RANKL is an essential mediator of osteoclast formation, function, and survival [177], and both preclinical and clinical data suggest that inhibition of RANKL is a viable strategy for the treatment of osteoporosis [178].”
Determining a multimodal aging clock in a cohort of Chinese women
Li, J., Xiong, M., Fu, X.-H., Fan, Y., Dong, C., Sun, X., Zheng, F., Wang, S.-W., Liu, L., Xu, M., et al. (2023) · Med · doi:10.1016/j.medj.2023.06.010 · Cited by 140
Postmenopausal Osteoporosis: The Role of Immune System Cells
Faienza, M. F., Ventura, A., Marzano, F., & Cavallo, L. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/575936 · Cited by 139
“The surface concentration of RANKL per cell was increased in postmenopausal women compared to premenopausal women and estrogen-treated postmenopausal women by two- to threefold for MSCs, T cells, B cells, and total RANKL expressing cells [47].”
Metadata
- Authors
- Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L.
- Affiliations
- Mayo Clinic (US)
- Amgen (United States) (US)
- Corresponding author
- Riggs, B. Lawrence
- Venue
- Journal of Clinical Investigation
- Published
- 2003-04-15
- Volume
- 111
- Issue
- 8
- Pages
- 1221-1230
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC152939
- OpenAlex
- W4254761345
- Cited by
- 825
- References
- 44
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 28 · 2023: 25 · 2022: 34 · 2021: 36 · 2020: 41 · 2019: 30 · 2018: 39 · 2017: 39 · 2016: 33 · 2015: 45 · 2014: 31 · 2013: 42 · 2012: 52
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- National Institutes of Health (M01-RR00 585, AG 04875, RR-00585)
- U.S. Public Health Service (AG-04875)
- National Institute on Aging (P01-AG04875, P01AG004875)
- National Center for Research Resources (M01-RR00 585, M01RR000585)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- RANK ligand, bone resorption, postmenopausal osteoporosis, estrogen deficiency, osteoclastogenesis, mesenchymal stem cells, T cells, B cells, osteoprotegerin, estradiol, bone turnover markers, paracrine signaling
- MeSH terms
- Adult, Bone Resorption, Carrier Proteins, Female, Flow Cytometry, Glycoproteins, Humans, Membrane Glycoproteins, Middle Aged, Tumor Necrosis Factor-alpha, Osteoporosis, Postmenopausal, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Apoptosis Regulatory Proteins, TNF-Related Apoptosis-Inducing Ligand, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.